PDCD1 and gastric cancer: The ATTRACTION-02 study found that the Programmed Cell Death Protein-1 (PD-1) inhibitor nivolumab resulted in prolonged OS in patients with advanced GC refractory to standard treatment (Kang et al., 2017).